Press Releases - 2005

	Jerusalem, Israel, March 30, 2006 Teva Expands Presence in China; Increases Equity Stake in Hualida Biotechnology to 60%
	Jerusalem, Israel, March 16, 2006 Teva Provides Update on Generic Pravachol Exclusivity
	Jerusalem, Israel, March 6, 2006 Teva Announces Tentative Approval of Topiramate Tablets, 50 Mg
	Jerusalem, Israel, February 28, 2006 Teva Reports Record Sales and Net Income for the Fourth Quarter and Full Year 2005
	Jerusalem, Israel, February 26, 2006 Teva Announces Tentative Approval of Ondansetron Injection USP
	Jerusalem, Israel, February 24, 2006 Teva Announces Exercise of Over-Allotment Option for Convertible Debentures
	Jerusalem, Israel, February 16, 2006 Teva Announces Tentative Approval of Rabeprazole Sodium Delayed-Release Tablets
	Jerusalem, Israel, February 13, 2006 Teva Announces Tentative Approval of Adenosine Injection
	Jerusalem, Israel, February 9, 2006 Teva Comments on Pfizer Press Release Regarding Azithromycin
	Jerusalem, Israel, February 8, 2006 Teva To Report 2005 Financial Results on February 28, 2006
	Jerusalem, Israel, February 1, 2006 Teva Announces Final Results of Merger Consideration in Connection With Ivax Acquisition
	Jerusalem, Israel, January 30, 2006 Teva Announces Global In-Market Fourth Quarter Sales of Its Blockbuster Copaxone® Increased 24% to $323 Million
	Jerusalem, Israel, January 29, 2006 Teva Announces Approval of Desmopressin Acetate Tablets
	Jerusalem, Israel, January 27, 2006 Teva Announces Pricing of $1.25 Billion of Convertible Debentures
	Jerusalem, Israel, January 27, 2006 Teva Announces Pricing of $1.5 Billion of Senior Notes
	Jerusalem, Israel, January 27, 2006 Teva Announces Favorable Court Decision Regarding Generic Allegra. District Court Denies Motion for Preliminary Injunction
	Jerusalem, Israel, January 26, 2006 Teva Completes Acquisition of Ivax
	Jerusalem, Israel, January 25, 2006 Teva Announces Offering of $2.75 Billion of Senior Notes and Convertible Debentures
	Jerusalem, Israel and Miami, Florida, January 23, 2006 U.S. Federal Trade Commission Clears Teva/IVAX Merger; Closing Scheduled for January 26, 2006
	Jerusalem, Israel, January 12, 2006 Teva Announces Tentative Approval of Divalproex Sodium Delayed-Release Tablets
	Jerusalem, Israel and Miami, Florida, January 10, 2006 Teva and IVAX Announce that FTC Review Process Continues on Track and Merger Closing is Expected Shortly
	Jerusalem, Israel and Miami, Florida, January 3, 2006 Teva and IVAX Decline "Public Acquirer Fundamental Change" Option for IVAX' 1.5% Convertible Senior Notes due 2025
	Jerusalem, Israel, January 1, 2006 Teva Announces Tentative Approval of Simvastatin Tablets
	Jerusalem, Israel and Miami, December 23, 2005 Teva and IVAX Sign Consent Order, Schedule Anticipated Closing Date for Merger
	Jerusalem, Israel, December 9, 2005 Teva Announces Approval of Cefprozil Tablets and Cefprozil for Oral Suspension Usp
	Jerusalem, Israel, December 9, 2005 Teva Announces Agreement with Cephalon Regarding Settlement of Provigil® Patent Litigation
	Jerusalem, Israel, December 7, 2005 Teva Announces Final Approval of Oxycodone ER Tablets, 10 Mg, 20 Mg and 40 Mg
	Jerusalem, Israel, December 7, 2005 Teva Issues Statement Regarding Outstanding Ivax Convertible Notes
	Jerusalem, Israel, December 5, 2005 Teva Announces Final Approval Of Ribavirin Tablets
	Jerusalem, Israel, December 2, 2005 Teva Announces FTC Will Not File Objections to Effexor® Xr Settlement
	Jerusalem, Israel, November 30, 2005 Teva Announces Tentative Approval of Zaleplon Capsules
	Jerusalem, Israel, November 24, 2005 Teva Draws Down on Recently Established US$ 350 Million Syndicated Loan Facility
	Jerusalem, Israel, November 24, 2005 Teva and Ivax Receive European Commission Approval for Acquisition
	Jerusalem, Israel, November 14, 2005 Teva Announces Approval of Azithromycin Tablets
	Jerusalem, Israel, November 8, 2005 Teva Reports Third Quarter 2005 Results
	Jerusalem, Israel, October 31, 2005 Teva Announces Approval of Glipizide and Metformin HCL Tablets
	Jerusalem, Israel, October 30, 2005 Teva to Report Third Quarter 2005 Financial Results on November 8, 2005
	Jerusalem, Israel and Miami, Florida, October 27, 2005 Teva and Ivax Shareholders Approve Pending Merger
	Jerusalem, Israel, October 21, 2005 Teva Receives Favorable Court Ruling on Generic Pravachol® Exclusivity
	Jerusalem, Israel, October 18, 2005 Teva and Wyeth Announce Settlement of Effexor Xr® Litigation
	Jerusalem, Israel and Miami, Florida, October 17, 2005 Teva/Ivax Cash and Stock Election Deadline Update
	Jerusalem, Israel, October 14, 2005 Teva Receives Favorable Ruling From Japanese Patent Office Regarding Pravastatin
	Jerusalem, Israel and Miami, Florida, October 11, 2005 Teva and IVAX Receive FTC Request for Additional Information
	Jerusalem, Israel, October 6, 2005 Teva Announces Tentative Approval of Gatifloxacin Tablets
	Jerusalem, Israel, October 6, 2005 Teva Announces Approval of Glimepiride Tablets
	Jerusalem, Israel, September 18, 2005 Teva Announces Tentative Approval of Ribavirin Tablets
	Jerusalem, Israel, September 14, 2005 Teva Announces Approval of Leflunomide Tablets
	Woodcliff Lake, NJ, September 6, 2005 Teva and Barr Announce Launch of Generic Allegra® Tablets by Teva Under Agreement With Barr
	Jerusalem, Israel, August 23, 2005 Court Grants Teva Summary Judgment of Non-Infringement on Gabapentin
	Jerusalem, Israel, August 18, 2005 Teva Announces Tentative Approval of Granisetron Hydrochloride Injection
	Jerusalem, Israel, August 16, 2005 Teva Announces Approval of Paroxetine HCL Tablets
	Jerusalem, Israel, August 12, 2005 Teva Announces Tentative Approval of Risedronate Sodium Tablets
	Jerusalem, Israel, August 7, 2005 Teva Receives Follow-Up Approvable Letter from FDA Regarding Agilect®
	Jerusalem, Israel, August 1, 2005 Teva Reports Second Quarter 2005 Results
	Jerusalem, Israel, July 26, 2005 Teva to Report Second Quarter 2005 Financial Results on August 1, 2005
	Jerusalem, Israel and Miami, Florida, July 25, 2005 Teva to Acquire Ivax for $ 7.4 Billion
	Jerusalem, Israel, July 25, 2005 Teva Comments on Market Rumors
	Jerusalem, Israel, July 20, 2005 Teva Announces Tentative Approval of Fexofenadine HCL Tablets
	Jerusalem, Israel, July 19, 2005 Teva Announces Tentative Approval Of Tramadol And Acetaminophen Tablets
	Jerusalem, Israel, July 19, 2005 Teva Announces Record Global In-Market Copaxone® Sales of $291 Million in The Second Quarter, an Increase of 29%
	Jerusalem, Israel, July 6, 2005 Teva Comments On Fda Letter Regarding Pravastatin Exclusivity
	Jerusalem, Israel, June 30, 2005 Teva Announces Final Approval Of Mirtazapine Orally Disintegrating Tablets
	Jerusalem, Israel, June 28, 2005 Teva And Active Biotech Announce The Submission Of An Ind To The Fda For Laquinimod, An Oral Product For The Treatment Of Relapsing Ms
	Jerusalem, Israel, June 28, 2005 Teva Announces Tentative Approval Of Glimepiride Tablets
	Jerusalem, Israel, June 27, 2005 Teva And Lundbeck Announce That Azilect (Rasagiline) For Parkinson's Disease Is Now Available In The United Kingdom
	Jerusalem, Israel, June 5, 2005 Teva Comments On Clarithromycin Er Preliminary Injunction
	Jerusalem, Israel, June 1, 2005 Teva Announces Approval Of Clarithromycin Tablets Usp, 250 Mg And 500 Mg
	Jerusalem, Israel, May 29, 2005 Teva Announces Tentative Approval Of Zolpidem Tartrate Tablets
	Jerusalem, Israel, May 20, 2005 Teva Comments On Clarithromycin Er Tablet Litigation
	Jerusalem, Israel, May 18, 2005 Teva Announces Approval Of Clarithromycin Er Tablets
	Jerusalem, Israel, May 16, 2005 Teva's Fenofibrate Product Receives Final Approval; Seeks Three Times Its Lost Profits In Antitrust Lawsuit Against Abbott
	Jerusalem, Israel,, May 2, 2005 Teva To Broadcast First Quarter 2005 Earnings Luncheon On The Web
	Jerusalem, Israel, May 2, 2005 Teva To Report First Quarter 2005 Financial Results On May 3, 2005
	Jerusalem, Israel, April 13, 2005 Teva Announces Approval Of Metformin Hcl Extended Release Tablets, 750 Mg
	Jerusalem, Israel, March 27, 2005 Teva Announces Tentative Approval Of Amlodipine Besylate Tablets
	Jerusalem, Israel and Stockholm, Sweden, March 22, 2005 Teva and Active Biotech Announce That Laquinimod Phase II Data Has Been Published Today in Neurology
	Jerusalem, Israel, February 24, 2005 Teva Announces Approval Of Methylprednisolone Acetate Injectable Suspension
	Jerusalem, Israel and Copenhagen, Denmark, February 22, 2005 Teva and Lundbeck Announce European Approval for AZILECT® (rasagiline) 1mg for Parkinson's Disease
	Jerusalem, Israel, February 17, 2005 Teva Announces Settlement Of Lamictal® Litigation With Glaxosmithkline
	Jerusalem, Israel, February 16, 2005 Teva and Gamida-Cell Will Develop and Commercialize StemEx® for the Treatment of Leukemia
	Jerusalem, Israel, February 16, 2005 Teva To Broadcast Fourth Quarter 2004 Earnings Luncheon On The Web
	Jerusalem, Israel, February 15, 2005 Teva Reports Record Sales and Net Income For Q4 2004
	Jerusalem, Israel, February 13, 2005 Teva Announces Tentative Approval Of Levofloxacin Injection
	Jerusalem, Israel, February 11, 2005 Teva And Savient Launch Tev-Tropin™ For Pediatric Growth Hormone Deficiency
	Jerusalem, Israel, February 10, 2005 Teva Announces Approval Of Amoxicillin And Clavulanate Potassium Chewable Tablets
	Jerusalem, Israel, February 2, 2005 Teva To Report 2004 Financial Results On February 15, 2005
	Jerusalem, Israel, January 28, 2005 Teva Announces Court Of Appeals Grants Favorable Ruling On Once-A-Week Version Of Fosamax®
	Jerusalem, Israel, January 28, 2005 Teva Announces Approval Of Glyburide/Metformin Hcl Tablets
	Jerusalem, Israel, January 26, 2005 Teva Announces Final Approval Of Levofloxacin Tablets, 750 Mg
	Jerusalem, Israel, January 26, 2005 Teva Announces Global In-Market Fourth Quarter Sales Of Copaxone® Increased 26% To $261 Million
	Jerusalem, Israel, January 14, 2005 Teva Announces Approval Of Fluconazole Injection
	Jerusalem, Israel, January 3, 2005 Teva Announces That Azilect® (Rasagiline) Is Approved For Marketing In Israel